The effect of Probiotics on control of clinical features of Bronchiectasis

The effect of Probiotics on control of clinical features and exacerbation of Bronchiectasis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017041514085N4

Enrollment

Registered

2017-08-01

Start date

2017-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchiectasis. Bronchiectasis

Interventions

Intervention 1: Intervention group 1(intervention group)will received routine drugs for treatment, they will treated with lactocare for 6 months. Intervention 2: Intervention group 2 (control group )

Treatment - Drugs

Placebo

Intervention group 1(intervention group)will received routine drugs for treatment, they will treated with lactocare for 6 months

Intervention group 2 (control group ) will received routine drugs for treatment and placebo during 6 months

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: More than 18 years, Not being Pregnant; Exclusion criteria: Cardiovascular diseases; Diabetes; Use of immunosuppressive agents; Bronchiectasis due to foreign body or tumor; Disable to do spirometry

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of cough. Timepoint: The same 6 month of last year and at during of intervention. Method of measurement: by asking the person.;Amount of sputum. Timepoint: The same 6 month of last year and before of intervention and end of sixth months. Method of measurement: by asking the person.;Severity of dyspnea. Timepoint: The same 6 month of last year and at during of intervention. Method of measurement: by asking the person base on MRC scale.;Results of sputum culture. Timepoint: before of intervention and end of sixth month. Method of measurement: smear and anti biogram.;FEV1, FVC, FEV1/FVC. Timepoint: before of intervention and end of sixth month. Method of measurement: spirometry.;Body mass index. Timepoint: before of intervention and end of sixth month. Method of measurement: weight over square of height.	—

Measure

Time frame

Severity of cough. Timepoint: The same 6 month of last year and at during of intervention. Method of measurement: by asking the person.;Amount of sputum. Timepoint: The same 6 month of last year and before of intervention and end of sixth months. Method of measurement: by asking the person.;Severity of dyspnea. Timepoint: The same 6 month of last year and at during of intervention. Method of measurement: by asking the person base on MRC scale.;Results of sputum culture. Timepoint: before of intervention and end of sixth month. Method of measurement: smear and anti biogram.;FEV1, FVC, FEV1/FVC. Timepoint: before of intervention and end of sixth month. Method of measurement: spirometry.;Body mass index. Timepoint: before of intervention and end of sixth month. Method of measurement: weight over square of height.

—

Secondary

Measure	Time frame
Need of prophylactic antibiotic for disease exacerbation. Timepoint: during of intervention. Method of measurement: by asking the person.;Rate of hospitalizations. Timepoint: during of intervention. Method of measurement: by asking the person.;Rate of exacerbation of disease. Timepoint: during of intervention. Method of measurement: by asking the person.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Shabnam Ziapour

Inflammatory Lung Disease Research Center

shabnam_ziapour@yahoo.com+98 133542460

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026